company background image
ER4 logo

Emergent BioSolutions DB:ER4 Stock Report

Last Price

€2.29

Market Cap

€117.7m

7D

1.9%

1Y

-75.2%

Updated

27 Mar, 2024

Data

Company Financials +

Emergent BioSolutions Inc.

DB:ER4 Stock Report

Market Cap: €117.7m

ER4 Stock Overview

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States.

ER4 fundamental analysis
Snowflake Score
Valuation3/6
Future Growth4/6
Past Performance0/6
Financial Health2/6
Dividends0/6

Emergent BioSolutions Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Emergent BioSolutions
Historical stock prices
Current Share PriceUS$2.29
52 Week HighUS$12.00
52 Week LowUS$1.38
Beta1.22
1 Month Change-12.20%
3 Month Change6.72%
1 Year Change-75.24%
3 Year Change-97.03%
5 Year Change-94.96%
Change since IPO-72.27%

Recent News & Updates

Recent updates

Shareholder Returns

ER4DE BiotechsDE Market
7D1.9%2.1%1.9%
1Y-75.2%37.0%7.3%

Return vs Industry: ER4 underperformed the German Biotechs industry which returned 37% over the past year.

Return vs Market: ER4 underperformed the German Market which returned 7.3% over the past year.

Price Volatility

Is ER4's price volatile compared to industry and market?
ER4 volatility
ER4 Average Weekly Movement22.3%
Biotechs Industry Average Movement5.8%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.1%
10% least volatile stocks in DE Market2.4%

Stable Share Price: ER4's share price has been volatile over the past 3 months.

Volatility Over Time: ER4's weekly volatility has increased from 17% to 22% over the past year.

About the Company

FoundedEmployeesCEOWebsite
19981,600Joe Papahttps://www.emergentbiosolutions.com

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector.

Emergent BioSolutions Inc. Fundamentals Summary

How do Emergent BioSolutions's earnings and revenue compare to its market cap?
ER4 fundamental statistics
Market cap€117.66m
Earnings (TTM)-€702.47m
Revenue (TTM)€969.24m

0.1x

P/S Ratio

-0.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ER4 income statement (TTM)
RevenueUS$1.05b
Cost of RevenueUS$807.10m
Gross ProfitUS$242.20m
Other ExpensesUS$1.00b
Earnings-US$760.50m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-14.57
Gross Margin23.08%
Net Profit Margin-72.48%
Debt/Equity Ratio132.5%

How did ER4 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.